Dear Editor
We read the paper "Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma" by Dr. Scheiner et al. published in a recent issue of Liver Cancer [1] with great interest. In this elegant study including 626 patients with unresectable hepatocellular carcinoma (HCC), the authors show that thrombocytopenia was highly prevalent and associated with favorable baseline tumor characteristics: smaller tumor diameter, less extrahepatic spread and vascular invasion, and earlier Barcelona Clinic Liver Cancer stages as compared to patients with normal platelet count. Notably, thrombocytopenia was also linked with longer overall survival, and these results were confirmed in their validation cohort (n = 525). This study shows the potential application of platelet count as a distinct prognostic marker for HCC. Although these findings are interesting, a few issues may deserve further discussion.
We have recently investigated the role of platelet count in 3,561 HCC patients identified in Taiwan between 2002 and 2017 (unpublished data). With the definition of thrombocytopenia as platelet count < 150 × 10 9 /L and thrombocytosis as ≥300 × 10 9 /L at the time of diagnosis, patients with thrombocytosis more often had larger tumors and higher serum alpha-fetoprotein levels. They also had higher rates of vascular invasion (54% vs. 29% vs. 15%) and metastases (28% vs. 12% vs. 6%), respectively, for thrombocytosis, normal platelet, and thrombocytopenic patients. Importantly, thrombocytosis was independently associated with worse survival after adjusting for age, gender, liver disease etiology, Barcelona Clinic Liver Cancer stages, model for end-stage liver disease score, and alpha-fetoprotein level in the multivariate Cox model. However, contrary to the data by Dr. Scheiner et al., the overall survival was similar between thrombocytopenic patients and patients with normal platelet count.
It is well known that thrombocytopenia was often associated with the development of cirrhosis with or without HCC [2] . On the other hand, platelets also participate actively in almost every step of HCC carcinogenesis [3, 4] . Consistent with this notion, antiplatelet therapy was reported to associate with a reduction in risk of liver cancer [5, 6] . Alternatively, among patients with known HCC, the use of antiplatelet therapy has been associated with lower recurrence rate and improved survival after surgery [7] . Thrombocytosis has
